 The stock has pulled back from the 2x pop after the recent data of EPI-7386Xtandi in post-chemotherapy metastatic castration-resistant prostate cancer, mCRPC. The efficacy of the EPI-7386Xtandi combination in mCRPC beats that of currently approved drugs by a significant margin. 